One of Wall Street's major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying.

Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the Dow Jones Industrial Average, which closed 0.32% higher at 49,668, finished the day lower. The small-cap Russell 2000 was the big loser... Here Are Tuesday's Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.

DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ET TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Examine the evolution of Jazz's (JAZZ) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Jazz Pharmaceuticals remains a Strong Buy, with Q1 2026 results affirming robust growth and a successful pivot into oncology. JAZZ's oncology segment, led by Ziihera, Modeyso, and Zepzelca, is driving double-digit sales growth and diversifying away from legacy neuroscience revenues. Ziihera's Priority Review for HER2+ GEA and multiple late-stage trials position JAZZ for significant market expansion and $2B+ peak sales potential via a HER2+ 'pipeline-in-a-product.'

Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.